Skip to main content

Table 2 Concentrations of PFAAs, OCPs, PCBs and PBDEs before and 12 months after bariatric surgery

From: Persistent organic pollutants and non-alcoholic fatty liver disease in morbidly obese patients: a cohort study

 

Before surgery

12 months after surgery

Changea

  

Mean

Median (5th; 95th persentile)

 

Mean

Median (5th, 95th pers.)

Mean

Median (5th; 95th persentile.)

p-value*

Compound

nc

ng/ml

ng/ml

nc

ng/ml

ng/ml

%

%

 

PFHxA

161

0.16

0.03 (0.03; 0.59)

118

0.16

0.03 (0.03, 0.56)

150b

0.00 (-92; 1108)

0.67

PFOA

161

2.63

2.56 (1.04; 4.66)

118

2.60

2.50 (1.00, 4.80)

0.1

-4.8 (-30; 33)

0.017

PFNA

161

0.96

0.83 (0.30; 2.19)

118

0.97

0.84 (0.29, 2.55)

-1.2

-6.5 (-38; 46)

0.029

PFDA

161

0.27

0.23 (0.08; 0.60)

117

0.27

0.24 (0.08, 0.72)

4.4

-5.6 (-52; 92)

0.258

PFUnA

161

0.19

0.15 (0.02; 0.50)

118

0.18

0.13 (0.02, 0.54)

11

-3.3 (-77; 142)

0.042

PFHxS

161

1.42

1.18 (0.54; 2.90)

118

1.46

1.35 (0.50, 2.88)

9.9

4.3 (-50; 89)

0.332

PFOS

161

3.91

3.2 (0.89; 10.3)

118

3.91

3.32 (0.98, 8.76)

1.1

-3.4 (-32; 50)

0.038

sumPFCA

161

4.20

4.07 (1.8; 7.52)

118

4.17

3.94 (1.64, 7.77)

-1.0

-6.1 (-29; 33)

0.003

sumPFSA

161

5.33

4.49 (1.75; 12.3)

118

5.37

4.82 (1.93, 11.3)

1.2

-2.1 (-31; 45)

0.222

  

Mean

Median (5th; 95th pers.)

 

Mean

Median

Mean

Median (5th; 95th pers.)

p-value*

Compound

nc

ng/g lipid

ng/g lipid

nc

ng/g lipid

ng/g lipid

%

%

 

HCB

149

12.8

10.9 (5.24; 23.3)

95

24.1

18.3 (7.31, 56.9)

113

77 (-12; 330)

<0.001

BetaHCH

149

17.1

12.7 (2.60; 28.6)

95

19.2

17.6 (3.79, 41.3)

49

39 (-19; 147)

<0.001

Transnonachlor

149

9.30

7.26 (1.59; 24.8)

95

14.5

10.9 (1.92, 41.6)

73

58 (-1.5; 190)

<0.001

p,p′-DDE

149

151

100 (16.8; 504)

95

229

157 (23.3, 688)

73

67 (-2.0; 182)

<0.001

PCB-118

149

13.3

10.0 (3.09; 33.3)

95

21.3

18.4 (4.82, 52.8)

68

62 (-8.6; 182)

<0.001

PCB-153

149

75.4

62.8 (19.4; 193)

95

125

108 (28.4, 314)

73

61 (-0.10; 188)

<0.001

PCB-138

149

39.8

32.2 (10.0; 103)

95

64.5

55.3 (14.0, 181)

71

65 (6.4; 176)

<0.001

PCB-156

149

3.98

3.40 (0.91; 9.88)

95

6.64

6.15 (1.11, 15.5)

84

65 (-8.7; 254)

<0.001

PCB-180

149

42.0

35.8 (11.2; 109)

95

69.2

62.0 (13.9, 164)

74

60 (-19; 196)

<0.001

PCB-170

149

18.1

15.5 (4.74; 46.2)

95

29.7

28.0 (6.38, 65.4)

70

59 (-3.5; 182)

<0.001

BDE-47

149

3.47

1.99 (1.11; 7.01)

95

4.48

2.17 (1.33, 12.2)

31

12 (-40; 183)

0.001

BDE-153

149

1.32

0.92 (0.31; 3.54)

95

2.40

1.53 (0.33, 8.82)

80

61 (-27; 241)

<0.001

BDE-209

149

11.8

4.79 (1.60; 48.5)

95

15.4

5.02 (2.07, 62.7)

213

11 (-88; 1132)

0.436

sumPCB

149

193

163 (50.8; 482)

95

316

271 (72.2, 786)

72

62 (-3.6; 186)

<0.001

sumBDE

149

16.6

8.94 (3.71; 59.5)

95

22.3

11.8 (4.83, 75.6)

115

21 (-79; 633)

0.036

  1. *p-value from Wilcoxon signed-rank test
  2. aMean, median, 5th and 95th persentile of serum PFAAs and POP concentration changes from baseline to 12 months were calculated from changes in individual study subjects who had serum sample available at both time points (same n as in the 12 months after surgery column)
  3. bA few extreme values rise the mean of percent change, but median remains 0 as substantial number of results were < LOQ both before and after surgery
  4. cFor POPs n is smaller than for PFAAs both at baseline and at 12 months because for part of the study subjects lipid determination was not done at either time point